新型法尼类固醇 X 受体（FXR）激动剂-TQA3526 在中国健康志愿者中的安全性、耐受性、药代动力学和药效学：一项双盲、随机、安慰剂对照、剂量递增、食物效应 I 期研究

IF 4.9 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of medicine Pub Date : 2023-12-10 DOI:10.1080/07853890.2023.2264850

Jia Xu, Hong Zhang, Hong Chen, Xiaoxue Zhu, Haiyan Jia, Zhongnan Xu, Dandan Huo, Hong Zhang, Cuiyun Li, Yanhua Ding

{"title":"新型法尼类固醇 X 受体（FXR）激动剂-TQA3526 在中国健康志愿者中的安全性、耐受性、药代动力学和药效学：一项双盲、随机、安慰剂对照、剂量递增、食物效应 I 期研究","authors":"Jia Xu, Hong Zhang, Hong Chen, Xiaoxue Zhu, Haiyan Jia, Zhongnan Xu, Dandan Huo, Hong Zhang, Cuiyun Li, Yanhua Ding","doi":"10.1080/07853890.2023.2264850","DOIUrl":null,"url":null,"abstract":"Background: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC). This study aimed to evaluate the safety, to...","PeriodicalId":8371,"journal":{"name":"Annals of medicine","volume":"46 1","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study\",\"authors\":\"Jia Xu, Hong Zhang, Hong Chen, Xiaoxue Zhu, Haiyan Jia, Zhongnan Xu, Dandan Huo, Hong Zhang, Cuiyun Li, Yanhua Ding\",\"doi\":\"10.1080/07853890.2023.2264850\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC). This study aimed to evaluate the safety, to...\",\"PeriodicalId\":8371,\"journal\":{\"name\":\"Annals of medicine\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2023-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/07853890.2023.2264850\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07853890.2023.2264850","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

背景：TQA3526是一种新型法尼类固醇X受体激动剂，用于治疗非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）。本研究旨在评估TQA3526的安全性、有效性和耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

Background: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC). This study aimed to evaluate the safety, to...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of medicine 医学-医学：内科

CiteScore

4.90

自引率

0.00%

发文量

292

审稿时长

3 months

期刊介绍： Annals of Medicine is one of the world’s leading general medical review journals, boasting an impact factor of 5.435. It presents high-quality topical review articles, commissioned by the Editors and Editorial Committee, as well as original articles. The journal provides the current opinion on recent developments across the major medical specialties, with a particular focus on internal medicine. The peer-reviewed content of the journal keeps readers updated on the latest advances in the understanding of the pathogenesis of diseases, and in how molecular medicine and genetics can be applied in daily clinical practice.